Images List Premium Download Classic

Fatty Liver

Fatty Liver-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Pharmaceutical composition containing silybin
Tasly Pharmaceutical Group Co., Ltd.
February 15, 2018 - N°20180042893

A pharmaceutical composition for treating non-alcoholic fatty liver diseases consists of a silybin-phospholipid complex preparation and pu'er tea/tea product according to a weight ratio of 0. 5-2. 5:0. 3-10, wherein the silybin-phospholipid complex capsule preparation and the pu'er teat/tea product are separately packaged.
Pharmaceutical composition containing silibinin
Tasly Pharmaceutical Group Co., Ltd.
February 15, 2018 - N°20180042892

Disclosed is a pharmaceutical composition containing silibinin, which is prepared from the following bulk drugs by weight ratio: 8. 75-60 parts of silibinin, 15-65 parts of phospholipid, and 25-200 parts of pu'er tea extract. The drug has the function of treating non-alcoholic fatty liver.
Methods for treating metabolic disorders using fgf
Salk Institute For Biological Studies
February 08, 2018 - N°20180036377

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Deuterated chenodeoxycholic acid derivative and pharmaceutical composition comprising compound thereof
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
February 01, 2018 - N°20180030083

Disclosed are deuterated chenodeoxycholic acid derivatives and pharmaceutical compositions containing the deuterated chenodeoxycholic acid derivatives. In particular, disclosed is a deuterated chenodeoxycholic acid derivative of formula (i), or a crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutical composition containing the same. The deuterated chenodeoxycholic acid derivatives of formula (i) can be used to treat and/or ...
Use of interleukin-22 in the treatment of fatty liver disease
Generon (shanghai) Corporation Ltd.
February 01, 2018 - N°20180028614

The present invention relates to use of interleukin-22 (il-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of il-22 in decreasing the levels of transaminases is also provided.
Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
Gilead Apollo, Llc
January 25, 2018 - N°20180021341

The present invention provides methods of treating, stabilizing or lessening the severity or progression of a non-alcoholic fatty liver disease using an acc inhibitor alone or with one or more additional therapeutic agents.
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pharmaceutical compositions for combination therapy
Intercept Pharmaceuticals, Inc.
January 11, 2018 - N°20180008616

The present invention relates to a pharmaceutical composition comprising a combination of an fxr agonist and at least one lipid lowering agent (e. G., ppar-alpha agonist, ppar-delta agonist, ppar-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a fxr mediated disease or condition, such as primary biliary cirrhosis (...
Treatment for non-alcoholic fatty liver diseases
Dsm Ip Assets B.v.
January 04, 2018 - N°20180000775

The present invention relates to the use of mixtures of vitamin e and polyunsaturated fatty acids (pufas) as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse. This includes prevention, control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic ...
Biomarkers for fatty liver disease and methods using the same
Metabolon, Inc.
December 28, 2017 - N°20170370954

Biomarkers of nash, nafld, and fibrosis and methods for diagnosis (or aiding in the diagnosis) of nafld, nash and/or fibrosis are described herein. Additionally, methods of distinguishing between nafld and nash, methods of classifying the stage of fibrosis, methods of determining the severity of liver disease, methods of determining the severity of liver disease or fibrosis, and methods of ...
Ostreolysin, functionally related variant thereof, extract comprising ostreolysin and uses thereof
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
December 28, 2017 - N°20170368133

Disclosed are methods for treating, preventing and alleviating obesity, fatty liver syndrome, diabetes, one or more metabolic syndrome conditions or complications and/or cancer comprising administering an effective amount of ostreolysin, its functionally related variant, or an extract or mushroom extract comprising the same to subjects in need thereof.
Grape seed products for nonalcoholic fatty liver disease and other uses
The United States Of America, As Represented By The Secretary Of Ariculture
December 28, 2017 - N°20170368128

Embodiments described herein provide for uses of grape products, such as chardonnay grape products and grape seed flour, for use in promoting a healthy liver, promoting healthy fat content in a liver, for treating or preventing nafld, and other embodiments and uses as described herein.
Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
Genfit
December 28, 2017 - N°20170368007

The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of general formula (i) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, ...
Co-agonists of the glucagon and glp-1 receptors
Merck Sharp & Dohme Corp.
December 21, 2017 - N°20170360893

Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase iv (dpp-iv) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (glp-1) receptor and the glucagon (gcg) receptor, and the use of such glp-1 ...
Fatty Liver Patent Pack
Download + patent application PDFs
Fatty Liver Patent Applications
Download + Fatty Liver-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Fatty Liver-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
Ucl Business Plc
December 14, 2017 - N°20170354627

Disclosed herein are methods of preventing, treating, and delaying the onset or progression of diseases associated with hepatic stellate cells (hscs), such as non-alcoholic fatty liver disease (nafld), fibrosis, and liver cancer, using ammonia-lowering therapies.
Biaryl derivative as gpr120 agonist
Lg Chem, Ltd.
December 07, 2017 - N°20170349594

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a gpr120 agonist, promoting glp-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory ...
New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted ...
Bayer Pharma Aktiengesellschaft
December 07, 2017 - N°20170349570

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such ...
Use of helminthostachys zeylanica, ugonins or flavone-based compounds for the treatment or prevention of metabolic ...
National Research Institute Of Chinese Medicine, Ministry Of Health And Welfare
December 07, 2017 - N°20170348367

Disclosed is a use of helminthostachys zeylanica, ugonins or compounds of formula (i) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose ...
Method of treating liver fibrosis
Chemocentryx, Inc.
December 07, 2017 - N°20170348293

A method of treating liver fibrosis with ccr2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (nafld), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (t2dm) or metabolic syndrome (ms).
Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
November 30, 2017 - N°20170340699

This invention generally relates to methods for treating or preventing the symptoms of non-alcoholic fatty liver disease, methods for reducing excessive fat from the liver, methods of improving glycemic control, and methods for treating or preventing liver dysfunction, that comprise administering a therapeutically effective amount of adenovirus 36 e4orf1 protein or functional variant thereof.
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
Alnylam Pharmaceuticals, Inc.
November 30, 2017 - N°20170340661

The present invention relates to rnai agents, e. G., double stranded rnai agents, targeting the patatin-like phospholipase domain containing 3 (pnpla3) gene, and methods of using such rnai agents to inhibit expression of a pnpla3 gene and methods of treating subjects having nonalcoholic fatty liver disease (nafld) and/or a pnpla3-associated disorder.
Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer
November 23, 2017 - N°20170334869

The present disclosure relates to benzamide compounds, prodrugs of the compounds, pharmaceutical compositions containing the compounds and/or the prodrugs and methods of using the compounds, prodrugs and pharmaceutical compositions in the treatment of diseases related to lipid metabolism including diabetes, non-alcholic fatty liver disease (nafld), non-alcholic steathohepatitis (nash), diseases caused by abnormal cell proliferation including cancer, psoriasis, and infectious ...
Loading